A detailed history of Bank Of America Corp transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 62,799 shares of JANX stock, worth $3.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
62,799
Previous 119,395 47.4%
Holding current value
$3.53 Million
Previous $5 Million 42.97%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$35.29 - $50.26 $2 Million - $2.84 Million
-56,596 Reduced 47.4%
62,799 $2.85 Million
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $3.37 Million - $6.21 Million
95,854 Added 407.18%
119,395 $5 Million
Q1 2024

May 15, 2024

SELL
$7.93 - $49.75 $160,661 - $1.01 Million
-20,260 Reduced 46.25%
23,541 $886,000
Q4 2023

Feb 14, 2024

BUY
$5.85 - $11.7 $132,525 - $265,051
22,654 Added 107.13%
43,801 $469,000
Q2 2023

Aug 14, 2023

SELL
$11.08 - $15.92 $28,697 - $41,232
-2,590 Reduced 10.91%
21,147 $251,000
Q1 2023

May 12, 2023

BUY
$11.25 - $22.21 $58,938 - $116,358
5,239 Added 28.32%
23,737 $287,000
Q4 2022

Feb 10, 2023

BUY
$11.1 - $18.26 $37,085 - $61,006
3,341 Added 22.04%
18,498 $243,000
Q3 2022

Nov 14, 2022

SELL
$10.82 - $16.84 $112,106 - $174,479
-10,361 Reduced 40.6%
15,157 $206,000
Q2 2022

Aug 12, 2022

SELL
$9.52 - $15.65 $148,902 - $244,781
-15,641 Reduced 38.0%
25,518 $311,000
Q1 2022

May 16, 2022

BUY
$13.24 - $20.24 $443,871 - $678,546
33,525 Added 439.15%
41,159 $590,000
Q4 2021

Feb 08, 2022

BUY
$15.44 - $27.32 $72,429 - $128,158
4,691 Added 159.4%
7,634 $150,000
Q3 2021

Nov 15, 2021

BUY
$20.7 - $34.69 $18,526 - $31,047
895 Added 43.7%
2,943 $63,000
Q2 2021

Sep 13, 2021

BUY
$18.58 - $25.37 $38,051 - $51,957
2,048 New
2,048 $52,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.34B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.